A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease | MicrobiomeTrials← Back to trialsNCT06546670
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-08-15Est. Completion: 2028-05-01
Enrollment target: 161 participants Locations- University of Alabama Birmingham, Birmingham, Alabama, United States
- Quotient Sciences Sea View, Miami, Florida, United States
- Boston Childrens Hospital, Boston, Massachusetts, United States
- Icahn School Of Med At Mount Sinai, New York, New York, United States
- Levine Cancer Insitute Carolinas Healthcare System, Charlotte, North Carolina, United States
- East Carolina University, Greenville, North Carolina, United States
- Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States
- Lifespan, Providence, Rhode Island, United States
- UT Health Science Center, Houston, Texas, United States
- Novartis Investigative Site, Ribeirão Preto, São Paulo, Brazil
- Novartis Investigative Site, São Paulo, São Paulo, Brazil
- Novartis Investigative Site, São Paulo, Brazil
- Novartis Investigative Site, Ankara, Sihhiye Altindag, Turkey (Türkiye)
- Novartis Investigative Site, Adana, Yuregir, Turkey (Türkiye)
Other microbiome trials you might be interested in
Sickle CellPKLR VariantsAdenosine Triphosphate Activities
Background:
Some people with the same disorder on a genetic level have more complications than others. Researchers want…
Bethesda, United StatesEst. completion Jul 1, 2027
HypertensionDiabetes
Background:
* Type 2 diabetes (T2D) and associated complications are major contributors to the global disease burden. T…
Accra, Ghana